Skip to Main Content
Wyss Institute
Menu
Search Site
Who We Are
About
How We Work
How We Collaborate
Team
Careers
Contact
Our Work
Technologies
Impact Report
Business Insider
Publications
Collaborations
AI DataHub
Brain Targeting Program
Collaborative Fund Alliance
Diagnostics Accelerator
Northpond Labs Alliance
Scientific Instrumentation Program
Newsroom
News
Press Resources
Multimedia
Events
Give
Search
News search results
17 Results for ''
Press Release
Expanding a lymph node, boosting a vaccine
May 6, 2024
Press Release
DNA origami-based vaccines toward safe and highly-effective precision cancer immunotherapy
March 15, 2024
Research Spotlights
Changing the calculus of cancer treatment
January 25, 2024
Community
Yang (Claire) Zeng on Developing DoriVac, the Next Generation of Vaccine Delivery Technology
September 28, 2022
Research Spotlights
Activating STING could make brain tumors more susceptible to treatment
July 14, 2022
Research Spotlights
New cancer vaccine delivers double punch to tumors
May 27, 2022
Press Release
Biomaterial vaccines ward off broad range of bacterial infections and septic shock
July 8, 2021
Awards
Harvard “Immuno-engineering to Improve Immunotherapy” (i3) Center at the Wyss Institute awards first grant to Dana-Farber cancer immunologist Eric Smith
January 21, 2021
Press Release
A viable vaccine for tough tumors
November 10, 2020
Research Spotlights
i3 Center: Biomaterials to Create T Cell Immunity
July 1, 2020
Awards
Harvard’s Wyss Institute announces cross-institutional “Immuno-engineering to Improve Immunotherapy (
i3
)” Center to advance cancer therapy
March 6, 2020
Press Release
A solid vaccine for liquid tumors
January 14, 2020
Research Spotlights
Harnessing Nature to Beat Cancer
February 28, 2019
Translation News
Harvard bioengineers’ biomaterial-based cancer immunotherapies to be developed by Novartis
March 20, 2018
Press Release
Personal cancer vaccines get their own boost
March 5, 2018
Press Release
Inciting an immune attack on cancer cells
August 25, 2015
Translation News
Cross-disciplinary team from Harvard University and Dana-Farber Cancer Institute brings novel therapeutic cancer vaccine to human clinical trials
September 6, 2013
Close search results
close menu
Who We Are
About
How We Work
How We Collaborate
Team
Careers
Contact
Our Work
Technologies
Impact Report
Business Insider
Publications
Collaborations
AI DataHub
Brain Targeting Program
Collaborative Fund Alliance
Diagnostics Accelerator
Northpond Labs Alliance
Scientific Instrumentation Program
Newsroom
News
Press Resources
Multimedia
Events
Give
Close menu
